Merck launches new Eeva Test version to optimise assisted reproductive outcomes

30 June 2015 (Last Updated June 30th, 2015 18:30)

Merck Serono has launched a new version of its early embryo viability assessment (Eeva) test to aid embryo assessment within assisted reproductive treatment (ART).

Eeva System

Merck Serono has launched a new version of its early embryo viability assessment (Eeva) test to aid embryo assessment within assisted reproductive treatment (ART).

Building upon the company's proven non-invasive Eeva test, the improved Eeva System 2.3 features an advanced Xtend Algorithm that enables ART labs to capture a more complete picture of embryo development.

When used adjunctively with legacy morphology, the algorithm increases the chances of identifying embryos that have the highest developmental potential compared to traditional morphology alone.

Merck Serono global strategy and franchises head Meeta Gulyani said: "Introducing the Eeva System 2.3 and its Xtend Algorithm shows our commitment to continuous innovation to ultimately improve success rates in ART.

"We see strong opportunities for scientific innovation in fertility technologies and will continue to invest in developing new products and evolving existing ones, such as the Eeva Test."

Extending beyond measurement of cell division timings, the algorithm features additional parameters, leading to five overall, which are applied to each embryo and mapped against a multi-dimensional prediction model.

"Introducing the Eeva System 2.3 and its Xtend Algorithm shows our commitment to continuous innovation."

Developed on a large data set from 12 sites, 373 women and 3,328 embryos, the algorithm was evaluated on an independent data set to demonstrate objective and consistent test results.

The non-invasive Eeva test may enhance IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability, when used adjunctively with traditional morphology.

In March 2014, Merck Serono received exclusive rights from Auxogyn to commercialise the latter's proprietary Eeva Test in Europe and Canada, with the option to extend to selected countries.

Auxogyn was granted the CE mark for Eeva in July 2012, and Merck will have launched the test in 13 countries across Europe and Canada, at the end of the first half of this year.


Image: The Eeva Test uses automated image analysis software to capture and analyse embryo cell activity that cannot be detected by the human eye. Photo: copyright Merck KGaA.